| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Mogroside IIe targets the IL-9/IL-9 receptor pathway, downregulating it. It also exhibits antioxidant, antidiabetic, and anticancer activities, similar to other mogrosides. As a precursor to mogroside V, it plays a crucial role in the metabolic pathway that leads to the production of the sweet and bioactive components of monk fruit.
|
|---|---|
| ln Vitro |
In vitro, Mogroside IIe demonstrates biological activity consistent with the mogroside class. It downregulates the IL-9/IL-9 receptor pathway. It also exhibits antioxidant, antidiabetic, and anticancer properties. Its bitter taste is a characteristic feature that distinguishes it from the sweet mogrosides.
|
| ln Vivo |
In vivo, Mogroside IIe is believed to contribute to the overall health benefits of monk fruit, particularly in its unripe form. Its ability to downregulate the IL-9 pathway suggests potential immunomodulatory effects. As a precursor to mogroside V, its presence in the fruit is essential for the development of the sweet taste and bioactivity of the mature fruit.
|
| Enzyme Assay |
The in vitro assay for Mogroside IIe's effect on the IL-9 pathway involves treating immune cells with the compound and measuring IL-9 production by ELISA. The expression of IL-9 receptor can also be measured by flow cytometry. For its other activities, antioxidant assays (DPPH, ABTS) and cell proliferation assays (MTT) can be performed.
|
| Cell Assay |
In vitro cell culture studies for Mogroside IIe utilize immune cells to study its immunomodulatory effects. Its anticancer activity is assessed in cancer cell lines using MTT assays. Its effect on glucose metabolism can be studied in skeletal muscle or liver cells. Its bitter taste can be studied using taste receptor-expressing cells.
|
| Animal Protocol |
In vivo animal experiments for Mogroside IIe are not extensively documented. However, its immunomodulatory effects could be studied in models of allergic or inflammatory diseases, where IL-9 plays a role. Its effects on glucose homeostasis could be studied in rodent models of type 2 diabetes.
|
| ADME/Pharmacokinetics |
Mogroside IIe has a molecular formula of C42H72O14 and a molecular weight of 801.01 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is more polar than its aglycone. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside IIe are limited, as it is a research compound. As a natural component of monk fruit, it is generally considered safe, though it is bitter and not used as a sweetener in its pure form. As a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Mogroside II-E is a steroidal saponin, β-D-glucoside, and 3-hydroxysteroid. It has been reported that mogroside IIe exists in Siraitia grosvenorii and other plants in the genus Siraitia, and relevant data are available for reference.
Mogroside IIe is a research compound with no clinical approval. It is a valuable tool for studying the biosynthesis of mogrosides and the pharmacology of bitter saponins. Its ability to downregulate the IL-9 pathway makes it a compound of interest for research into immunology and inflammation. |
| Molecular Formula |
C42H72O14
|
|---|---|
| Molecular Weight |
801.0127
|
| Exact Mass |
800.492
|
| CAS # |
88901-38-6
|
| PubChem CID |
24721558
|
| Appearance |
White to off-white solid powder
|
| Density |
1.40±0.1 g/cm3(Predicted)
|
| Boiling Point |
1048.3±65.0 °C(Predicted)
|
| LogP |
1.119
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
56
|
| Complexity |
1410
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@H]2CC[C@@]3([C@@]2(C[C@H]([C@@]4([C@H]3CC=C5[C@H]4CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)C)C
|
| InChi Key |
WVXIMWMLKSCVTD-JLRHFDOOSA-N
|
| InChi Code |
InChI=1S/C42H72O14/c1-20(9-13-29(39(4,5)52)56-37-35(51)33(49)31(47)25(19-44)54-37)21-15-16-40(6)26-12-10-22-23(42(26,8)27(45)17-41(21,40)7)11-14-28(38(22,2)3)55-36-34(50)32(48)30(46)24(18-43)53-36/h10,20-21,23-37,43-52H,9,11-19H2,1-8H3/t20-,21-,23-,24-,25-,26+,27-,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,40+,41-,42+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(3S,8S,9R,10R,11R,13R,14S,17R)-11-hydroxy-17-[(2R,5R)-6-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~124.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2484 mL | 6.2421 mL | 12.4842 mL | |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
